loading...| Preferred Name |
Atorvastatin Calcium |
|
| Synonyms |
|
|
| Definitions |
The calcium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C28837 |
|
| ALT_DEFINITION |
A drug used to lower the amount of cholesterol in the blood and to prevent stroke, heart attack, and angina (chest pain). It is also being studied in the prevention and treatment of some types of cancer and other conditions. Atorvastatin calcium blocks an enzyme that helps make cholesterol in the body. It also causes an increase in the breakdown of cholesterol. It is a type of HMG-CoA reductase inhibitor and a type of statin. |
|
| CAS_Registry |
344423-98-9 134523-03-8 |
|
| CHEBI_ID |
CHEBI:2911 |
|
| Chemical_Formula |
2C33H34FN2O5.Ca.3H2O |
|
| code |
C28837 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
The calcium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation. |
|
| Display_Name |
Atorvastatin Calcium |
|
| FDA_UNII_Code |
48A5M73Z4Q |
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Atorvastatin Calcium |
|
| Legacy Concept Name |
Atorvastatin |
|
| Maps_To |
Atorvastatin Calcium |
|
| NCI_Drug_Dictionary_ID |
460239 |
|
| PDQ_Closed_Trial_Search_ID |
460239 |
|
| PDQ_Open_Trial_Search_ID |
460239 |
|
| Preferred_Name |
Atorvastatin Calcium |
|
| prefixIRI |
NCIT:C28837 |
|
| prefLabel |
Atorvastatin Calcium |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0286650 |
|
| subClassOf |